

BC PharmaCare Drug Information

The drug below is being considered for possible coverage under the B.C. PharmaCare program. PharmaCare is a government-funded drug plan that helps British Columbians with the cost of eligible prescription drugs and specific medical supplies. For more information on PharmaCare, visit [Ministry of Health - PharmaCare](#).

PharmaCare reviews each drug for treating a specific illness or medical condition (known as an “indication”). If a decision is made to cover the drug, it will be only for that illness or condition.

In some cases, PharmaCare may cover a drug only for people who have the illness or condition and have not responded to other drugs used to treat that illness or condition.

For more information on PharmaCare’s drug coverage review process, see the last page of this information sheet.

Information about the drug	
Generic name (scientific name)	propiverine
Brand name	Mictoryl™ and Mictoryl™ Pediatric
Manufacturer	Duchesnay Inc.
Indication	Overactive Bladder (OAB)
Has the drug been reviewed by the Common Drug Review (CDR)? (see the note below this table.)	Yes. For more information about the CDR’s review of propiverine (MICTORYL™), you can Search the CDR Reports .
Public input start date	Wednesday February 15, 2017
Public input closing date	Wednesday March 15, 2017 AT MIDNIGHT
How is the drug taken?	Mictoryl™ is taken orally (by mouth).
How often is the drug is taken?	Adults take Mictoryl™ once daily. Children and adolescents take Mictoryl™ Pediatric twice daily.

Information about the drug	
General drug and/or drug study information	<p>Mictoryl™ is used in adults who have Overactive Bladder (OAB). The symptoms of OAB include the urgent need to urinate, needing to urinate more often or being unable to hold your urine.</p> <p>Mictoryl™ Pediatric is used in children with OAB from the age of 5 years up to a body weight of 35 kg.</p> <p>Mictoryl™ works by stopping the bladder from contracting and increasing the amount of urine that the bladder can hold.</p> <p>Studies looked at the following to determine if Mictoryl™ is safe and helpful for the treatment of OAB:</p> <ul style="list-style-type: none"> • Change in the number of incontinence episodes per 24 hours • Number of micturitions (passing of urine) per day • Impact of treatment on the quality of life as measured by King’s Health Questionnaire (KHQ) • Bad reactions • Serious bad reactions • Patients leaving the trial due to bad reactions • Bad reactions of special interest: dry mouth, vision blurred, constipation
Other considerations	None

Note:

The Common Drug Review (CDR) is a national organization that reviews drugs on behalf of Canadian public sector plans when manufacturers want to have the jurisdictions provide coverage for the drugs. For detailed information on B.C. PharmaCare’s drug review process, including the role of the CDR in that process, see [The Drug Review Process in B.C. - Overview](#).

Cost of the drug under review compared to other drugs used to treat OAB in adults			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Annual Cost of Therapy
propiverine hydrochloride (Mictoryl™)	Under Review	30 mg daily, increasing to 45 mg daily if needed	507
darifenacin (Enablex™)	Non-Benefit	7.5 mg to 15 mg daily	588
fesoterodine fumarate (Toviaz™)	Non-Benefit	4 to 8 mg daily	548
mirabegron (Myrbetriq™)	Non-Benefit	25 to 50 mg once daily	533
onabotulinumtoxinA (Botox®)	Under Review	100 units/dose every: 3 months 4 months	1,428 1,071

Cost of the drug under review compared to other drugs used to treat OAB in adults			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Annual Cost of Therapy
oxybutynin chloride (generics)	Regular Benefit	5 mg 2 to 3 times daily	72 to 108
oxybutynin (Oxytrol™)	Non-Benefit	one patch twice weekly	676
oxybutynin chloride (Gelnique®)	Non-Benefit	one 1 g sachet daily	721
oxybutynin chloride ER (Ditropan® XL)	Non-Benefit	5 to 30 mg daily	850 - 2,550
solifenacin succinate (generics)	Limited Coverage	5 to 10 mg daily	154
tolterodine ER (generics)	Non-Benefit	4 mg daily	179
tolterodine (generics)	Non-Benefit	2 mg twice daily	179
tropium chloride (Trosec®)	Non-Benefit	20 mg twice daily	595

Note: All prices are from the CDR Pharmacoeconomic Report for propiverine hydrochloride (Mictoryl™)

Cost of the drug under review compared to other drugs used to treat OAB in children			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Annual Cost of Therapy
propiverine hydrochloride (Mictoryl™ Pediatric)	Under Review	10 to 30 mg daily in two to three doses based on weight as laid out in monograph table	270 - 810
oxybutynin chloride (generics)	Regular Benefit	5 mg twice daily	Tablets - 72 Oral syrup - 162
<i>Comparators without a pediatric indication</i>			
darifenacin (Enablex™)	Non-Benefit	7.5 mg to 15 mg daily	588
fesoterodine fumarate (Toviaz™)	Non-Benefit	4 to 8 mg daily	548
mirabegron (Myrbetriq™)	Non-Benefit	25 to 50 mg once daily	533

Cost of the drug under review compared to other drugs used to treat OAB in children			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Annual Cost of Therapy
solifenacin succinate (generics)	Limited Coverage	5 to 10 mg daily	154
tolterodine ER (generics)	Non-Benefit	4 mg daily	179
tolterodine (generics)	Non-Benefit	2 mg twice daily	179
tropium chloride (Trosec®)	Non-Benefit	20 mg twice daily	595

Note: All prices are from the CDR Pharmacoeconomic Report for propiverine hydrochloride (Mictory™)

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, visit: [The Drug Review Process in B.C. - Overview](#).

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.